CN105949323A - EpCAM-specific chimeric antigen receptor and encoding gene and application thereof - Google Patents
EpCAM-specific chimeric antigen receptor and encoding gene and application thereof Download PDFInfo
- Publication number
- CN105949323A CN105949323A CN201610483048.1A CN201610483048A CN105949323A CN 105949323 A CN105949323 A CN 105949323A CN 201610483048 A CN201610483048 A CN 201610483048A CN 105949323 A CN105949323 A CN 105949323A
- Authority
- CN
- China
- Prior art keywords
- epcam
- antigen receptor
- chimeric antigen
- specific chimeric
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 title claims abstract description 79
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 44
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 title claims abstract 17
- 108090000623 proteins and genes Proteins 0.000 title claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 17
- 230000003834 intracellular effect Effects 0.000 claims abstract description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims abstract description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 3
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 2
- 210000004698 lymphocyte Anatomy 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 230000004048 modification Effects 0.000 abstract description 2
- 150000007523 nucleic acids Chemical group 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 66
- 210000004027 cell Anatomy 0.000 description 50
- 238000001514 detection method Methods 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 230000009471 action Effects 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000012804 EPCAM Human genes 0.000 description 2
- 101150084967 EPCAM gene Proteins 0.000 description 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 101150057140 TACSTD1 gene Proteins 0.000 description 2
- 229950009084 adecatumumab Drugs 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses an EpCAM (Epithelial cell adhesion molecule)-specific chimeric antigen receptor. The EpCAM-specific chimeric antigen receptor is obtained by serially connecting a single-chain antibody of a human anti-EpCAM, CH2CH3 of a human antibody IgG1, a transmembrane region and an intracellular signal structure of CD28, an intracellular signal structure of CD137 and an intracellular signal structure of CD3[zeta]. The invention further discloses an amino acid sequence and a nucleic acid sequence of the chimeric antigen receptor. The invention further discloses application of the chimeric antigen receptor to preparation of medicines for treating EpCAM-related tumors, namely modification of T lymphocytes, and the modified lymphocytes can be applied to treatment of the EpCAM-related tumors.
Description
Technical field
The present invention relates to cellular immunization technical field, particularly relate to a kind of EpCAM specific chimeric antigen and be subject to
Body and encoding gene, application.
Background technology
EpCAM (Epithelial cell adhesion molecule) epithelial cell adhesion molecule belongs to adhesion molecule
Family, also referred to as 17-A, ESA, EGP40, Trop-1, KSA, CD326, TACSTDI, C017-1A,
GA733-2 etc..EpCAM is a kind of to be correlated with Ca2+ oscillations transduction I (tumor-associated calcium by tumor
Signaltransducerl, TACSTDI) the single pass transmembrane albumen of a molecular weight 30～40kDa of gene code,
Participate in regulation cell adhesion, mediated signal transduction, cell migration, breed and the function such as differentiation (Kurtz JE,
DufourP.Adecatumumab:an ant1-EpCAM monoclonal antibody,from the bench to
the bedside[J].Expert Opin BioITher,2010,10(6):951-958；Trzpis M,McLaughlin
PM,de LeijLM,et al.Epithelial cell adhesion molecule.More than a carcinoma
marker andadhesion molecule[J].Am J Pathol,2007,171(2):386-395)。
EpCAM expresses on people's part normal epithelium cell and most of malignant epithelial cell surface, the most generally
Think that the biological characteristics of tumor is played an important role by it.Under pathologic condition, EpCAM is almost expressed in all
Adenocarcinoma in, including Colon and rectum adenocarcinoma, adenocarcinoma of stomach, breast carcinoma, ovarian cancer, adenocarcinoma of lung, carcinoma of prostate,
Cancer of pancreas and hepatocarcinoma, retinoblastoma (Kurtz JE, Dufour P.Adecatumumab:an
ant1-EpCAM monoclonal antibody,from thebench to the bedside[j].Expert Opin
BiolTher,2010,10(6):951-958).Research finds that EpCAM is also the labelling of some tumor stem cells
Thing, the research of Kimura etc. finds that liver-cancer stem cell positive for EpCAM can induce the mice of immunodeficiency
There is tumor (Kimura O, Takahashi T, Ishii N, et al.Characterization oftheepithelial cell
adhesion molecule(EpCAM)+cell population in hepatocellularcarcinoma cell lines
[J] .Cancer Sci, 2010,101 (10): 2145-2155.).By positive for hepatocarcinoma EpCAM and negative sub-
Group's cell is expelled in the Mice Body of immunodeficiency respectively, and result display forms the cancerous cell number needed for tumor
EpCAM positive is far fewer than EpCAM negative patient, and the mice of injection EpCAM positive cancer cell is produced
Raw tumor is bigger than injection EpCAM negative patient, and the positive cancerous cell oncogenicity ratio of EpCAM is described
Cancerous cell negative for EpCAM is big.Subgroup clone's speed positive for EpCAM in hepatocellular carcinoma cells system is far away
More than the subgroup that EpCAM is negative.Research also finds, cancerous cell positive for EpCAM can be divided into
The cell that EpCAM is positive and negative, and the cancerous cell of EpCAM feminine gender can only be divided into EpCAM feminine gender
Cell, illustrate that cancerous cell positive for EpCAM has the potential of multinomial differentiation.
The expression of EpCAM is relevant to the prognosis of tumor, can be as neoplasm targeted therapy a target site.
The antibody of EpCAM obtains FDA approval treatment cancer ascites at present in Europe, but there is presently no EpCAM
CART in clinical practice.
Summary of the invention
The technical problem existed based on background technology, it is an object of the invention to provide a kind of EpCAM special
Sex-mosaicism antigen receptor.
The present invention also aims to provide the gene encoding above-mentioned Chimeric antigen receptor.
The present invention also aims to provide the application of above-mentioned Chimeric antigen receptor.
To achieve these goals, a kind of EpCAM specific chimeric antigen receptor that the present invention proposes, its
The single-chain antibody of born of the same parents' exoantigen land behaviour anti-EpCAM.
Preferably, the aminoacid sequence of the single-chain antibody of described people's anti-EpCAM is as shown in SEQ ID NO.1.
Preferably, there is a connection between heavy chain and the light chain molecule of the single-chain antibody of described embedding people's anti-EpCAM
Peptide, its aminoacid sequence is as shown in SEQ ID NO.2.
Preferably, the amino terminal of described Chimeric antigen receptor contains a signal peptide, and its aminoacid sequence is such as
Shown in SEQ ID NO.3.
Preferably, described Chimeric antigen receptor is by the single-chain antibody of people's anti-EpCAM, people's IgG antibody 1
The cross-film district of CH2CH3, CD28 and intracellular signal structure, the intracellular signal structure of CD137, CD3 ζ
Intracellular signal structures in series is constituted.
Preferably, the cross-film district of described CD28 and intracellular signal structure, CD137 intracellular signal structure, CD3 ζ
Intracellular signal structures in series constitute domain be T cell costimulatory signal conducting structure.
Preferably, the aminoacid sequence such as SEQ ID NO.4 institute of described T cell costimulatory signal conducting structure
Show.
Preferably, the aminoacid sequence of described Chimeric antigen receptor is as shown in SEQ ID NO.5.
The gene encoding above-mentioned EpCAM specific chimeric antigen receptor that the present invention also proposes, its nucleic acid sequence
Row are as shown in SEQ ID NO.6.
The above-mentioned EpCAM specific chimeric antigen receptor that the present invention also proposes is in preparation treatment EpCAM phase
Close the application in tumour medicine.
The heavy chain of the human-derived anti-human EpCAM antibody that the present invention delivered according to calendar year 2001 and the variable region sequence of light chain
Row (Raum, 2001Cancer Immunol Immunother.Stefanie 2002, Int.J.Cancer), pass through
Codon optimized, the ScFv sequence of gene chemical synthesis anti-EpCAM, and synthesis ScFv is cloned into
In pSFG-CH2CH3-CD28-CD137-CD3 ζ, i.e. construction cost is invented
EpCAM-scFv-CH2CH3-CD28-CD137-CD3 ζ Chimeric antigen receptor.
The present invention utilizes Chimeric antigen receptor and reversal of viral packaging plasmid PeqPam3 and RD114env to exist
293T cell is packaged into reversal of viral, utilizes this virus to infect T lymphocyte.Elisa is utilized to detect CAR-T
Cell is the secretion of IFN-γ under antigenic stimulus, and by the flow cytometer detection tumor cell to the EpCAM positive
Lethal effect.
The present invention announces the structure of the specific Chimeric antigen receptor of EpCAM, and Infection in Vitro T lymph is thin
The technology of born of the same parents.The killing tumor cells such as the T lymphocyte release IFN-γ after modification.EpCAM specificity
Chimeric antigen receptor to may be used for EpCAM related neoplasms (as female thin in adenocarcinoma, hepatocarcinoma, retina
Born of the same parents' tumor etc.) targeted therapy.
Accompanying drawing explanation
Fig. 1 is the structural representation of the EpCAM specific chimeric antigen receptor that the present invention proposes.
Fig. 2 is the electrophoretogram of the PCR primer of gained EpCAM-scFv of the present invention.
Fig. 3 is the electrophoretogram of gained EpCAM specific chimeric antigen receptor of the present invention.
Fig. 4 is the result figure of the expression of CAR molecule in flow cytometer detection EpCAM specific C AR-T cell.
Fig. 5 is the ratiometric result figure of flow cytometry tumor cell and T cell.
Fig. 6 is gained Chimeric antigen receptor EpCAM specific C AR-T cell of the present invention and lymphoma cell
MTT testing result figure.
Fig. 7 is that ELISA detects gained CAR-T cell of the present invention IFN-γ after being stimulated by EpCAM
Expression of results figure with IL2.
Detailed description of the invention
Below, by specific embodiment, technical scheme is described in detail.
The structure of embodiment 1:EpCAM specific chimeric antigen receptor reversal of viral carrier
A kind of EpCAM specific chimeric antigen receptor that the present invention proposes, by the strand of people's anti-EpCAM
Antibody, the cross-film district of CH2CH3, CD28 of people's IgG antibody 1 and intracellular signal structure, the born of the same parents of CD137
Interior signal structure, the intracellular signal structures in series of CD3 ζ are constituted, its aminoacid sequence such as SEQ ID NO.1
Shown in.
1, utilize the human-derived anti-human EpCAM monoclonal antibody sequences that calendar year 2001 delivers, select VH and VL
Sequence, for designing the scFv sequence in CAR carrier, use Jin Sirui biotech company
Codon is optimized by OptimumGeneTM gene design software further, divides at the sequence two ends optimized
Not Jia Shang NcoI, BAMHI restriction enzyme site, the sequence after optimization is complete by Nanjing Jin Sirui biotech company
Becoming gene chemical synthesis, the sequence after synthesis is cloned in pCDNA3 carrier, and plasmid is named
EpCAM-scFv-pCDNA3。
The EpCAM-scFv Sequence wherein inserted can carry out amplification via PCR and obtain, and then carries out
Detection, as in figure 2 it is shown, wherein band 1 is the PCR primer of EpCAM-scFv, about 750bp；Bar
It it is the reference band of 100bp with 2.
2, EpCAM-scFv-pCDNA3 plasmid restricted enzyme NcoI and BAMHI enzyme action, enzyme
Cut system as follows: 2 μ g EpCAM-scFv-pCDNA3,1 μ L NcoI, 1 μ L BamHI, 2 μ L 10 × enzyme action
Buffer, mends 20 μ L with water, in 37 DEG C of water-baths overnight, digestion products with 1% agarose gel electrophoresis,
Under ultraviolet, cut purpose band, use DNA gel to reclaim test kit (AXYGEN company) and reclaim mesh
Fragment；With same method NcoI and BAMHI enzyme action pSFG-CH2CH3-CD28-CD137-CD3 ζ
Carrier, with agarose gel electrophoresis, reclaims purpose fragment.EpCAM-ScFv after reclaiming carries with enzyme action
Body is connected by T4DNA ligase, and reaction system is as follows: 2 μ L EpCAM-ScFv, 2 μ L carrier enzyme action
Product, 1 μ L 10 × connection buffer, 1 μ L ligase, mend 10 μ L with water, in 16 DEG C of water-baths overnight.
Take connection product to join in DH5 α competence [with reference to E. coli competent in " molecular cloning " third edition
Preparation (CaCl2Method)], place incubated overnight in 37 DEG C of bacteriological incubators.The single bacterium colony of picking, expands training
Support, extract the plasmid of positive colony, through enzyme action (Fig. 3) and order-checking, by named for correct carrier
The EpCAM specificity that EpCAM-scFv-CH2CH3-CD28-CD137-CD3 ζ, the i.e. present invention propose is embedding
Close antigen receptor.
Being detected by gained EpCAM specific chimeric antigen receptor, its result is as it is shown on figure 3, wherein
Band 1 is the comparison band of 100bp, and band 2 is gained EpCAM specific chimeric antigen receptor.
The preparation of the T lymphocyte that embodiment 2:EpCAM specific chimeric antigen receptor is modified
1. the packaging containing EpCAM specific chimeric antigen receptor reversal of viral
Retrovirus is extracted with without the operating instruction of (sky root is biological) in the big extraction reagent kit of endotoxin plasmid
Package carrier pRD114 and EpCAM-scFv-CH2CH3-CD28-CD137-CD3 ζ retroviral vector
Cotransfection is in 293T cell, and after transfection, 48h collects cell conditioned medium, and 4000rpm is centrifuged 10min, removes
Cell in supernatant and cell debris.With the membrane filtration of 0.45 μm, subpackage is frozen, standby.
The preparation of 2.T lymphocyte
Take the fresh anticoagulation of 20mL healthy volunteer, with lymph separation liquid (GE company) discrete periphery
Blood monocyte (PBMC).Cell CD3 and CD28 flat board after separation stimulate 48h, use T lymph
Cell culture medium GT-T551 (TAKARA company) adds 3% self blood plasma and induces, and obtains T lymph
Cell.
The preparation of 3.CAR-T cell
It is coated non-tissue culturing plate 24 orifice plate, often with the RetroNectin (TAKARA company) of 50 μ g/mL
Hole adds 500 μ L, and 4 DEG C overnight.Every hole adds 500 μ L viral supernatants, hatches 30min for 37 DEG C.Remove
Viral supernatants, adds 500 μ L viral supernatants, hatches 30min for 37 DEG C, and except viral supernatants, every hole adds
1.5mL viral supernatants, adds the T lymphocyte after 0.5mL dilution, thus obtains
EpCAM-scFv-CH2CH3-CD28-CD137-CD3 ζ cell, i.e. EpCAM specific C AR-T is thin
Born of the same parents.
4. the expression of CAR molecule in flow cytometer detection EPCAM specific C AR-T cell
CAR-T cell is added the anti-Fc antibody (Jackson company) of 5 μ L FITC labellings, hatches for 37 DEG C
After 1h, carry out flow cytometer detection, testing result as shown in Figure 4: the most left figure be comparison T lymphocyte,
Right figure is the retroviral T lymphocyte infecting Chimeric antigen receptor, as shown in Figure 4: this method institute
Obtain the efficiency of CAR-T cell more than 90%.
Embodiment 3: Chimeric antigen receptor EpCAM specific C AR-T cell is to EpCAM related neoplasms
Lethal effect
The lethality detection of 1.CAR-T cells against tumor
The colon cancer cell HT-29 culture medium that EpCAM is positive is adjusted to 5 × 106/ mL, every hole 50 μ L,
By effector lymphocyte and target cell ratio for 4:1, add oncocyte 2.5 × 105Individual, after cell is the most adherent, receive
Collection T cell and CAR-T cell, adjusting cell concentration is 1.25 × 106/ mL, every hole 50 μ L, then distinguish
Carry out fluidic cell (cultivating 24h) and MTT detection (cultivating 4h).
First, collect cell and carry out the dyeing of CD3, carry out flow cytometry tumor cell (CD3-) and
T cell (CD3+) ratio, its result is as shown in Figure 5.As shown in Figure 5: gained inosculating antibody of the present invention
Original receptor EpCAM specific C AR-T cell can effectively kill colon cancer cell.
Secondly, same experiment is abandoned supernatant and is added the CCK8 of 100 μ L dilutions, hatches 4 hours, microplate reader
The light absorption value of detection OD450.As shown in Figure 6, EpCAM is expressed its testing result by CAR-T cell
The tumor cell that the killing rate of tumor is not expressed higher than EpCAM；Related neoplasms is killed by CAR-T cell to be made
With higher than T cell, higher than media alone.
2.ELISA detection CAR-T cell IFN-γ and IL2 after being stimulated by EPCAM are expressed
Colon cancer cell HT-29 culture medium is adjusted to 5 × 106/ mL, every hole 50 μ L, add colon cancer
Cell HT-29 2.5 × 105Individual, after cell is the most adherent, collect T and CAR-T cell, adjust cell
Concentration is 1 × 106/ mL, every hole 50 μ L, cultivate 24h.Collect supernatant, utilize ELISA kit to examine
Survey IFN-γ and the expression of IL2.
Its result is as it is shown in fig. 7, the T lymphocyte that EpCAM specific chimeric antigen receptor is modified is being received
Express and secretion of gamma-IFN and IL2 after stimulating to colon cancer cell HT-29 positive for EpCAM.
The above, the only present invention preferably detailed description of the invention, but protection scope of the present invention not office
Being limited to this, any those familiar with the art is in the technical scope that the invention discloses, according to this
The technical scheme of invention and inventive concept thereof in addition equivalent or change, all should contain the protection in the present invention
Within the scope of.
Claims (10)
1. an EpCAM specific chimeric antigen receptor, it is characterised in that described Chimeric antigen receptor
The single-chain antibody of born of the same parents' exoantigen land behaviour anti-EpCAM.
EpCAM specific chimeric antigen receptor the most according to claim 1, it is characterised in that described
The aminoacid sequence of the single-chain antibody of people's anti-EpCAM is as shown in SEQ ID NO.1.
EpCAM specific chimeric antigen receptor the most according to claim 1 or claim 2, it is characterised in that
Individual connection peptides is had, its aminoacid between heavy chain and the light chain molecule of the single-chain antibody of described embedding people's anti-EpCAM
Sequence is as shown in SEQ ID NO.2.
4., according to EpCAM specific chimeric antigen receptor described in any one of claim 1-3, its feature exists
In, the amino terminal of described Chimeric antigen receptor contains a signal peptide, its aminoacid sequence such as SEQ ID
Shown in NO.3.
5., according to EpCAM specific chimeric antigen receptor described in any one of claim 1-4, its feature exists
In, described Chimeric antigen receptor by the single-chain antibody of people's anti-EpCAM, the CH2CH3 of people's IgG antibody 1,
The cross-film district of CD28 and intracellular signal structure, the intracellular signal structure of CD137, the intracellular signal of CD3 ζ
Structures in series is constituted.
6., according to EpCAM specific chimeric antigen receptor described in any one of claim 1-5, its feature exists
In, the cross-film district of described CD28 and intracellular signal structure, CD137 intracellular signal structure, the born of the same parents of CD3 ζ
Interior signal structure domain in series is T cell costimulatory signal conducting structure.
EpCAM specific chimeric antigen receptor the most according to claim 6, it is characterised in that described
The aminoacid sequence of T cell costimulatory signal conducting structure is as shown in SEQ ID NO.4.
8., according to EpCAM specific chimeric antigen receptor described in any one of claim 1-7, its feature exists
In, the aminoacid sequence of described Chimeric antigen receptor is as shown in SEQ ID NO.5.
9. coding gene of EpCAM specific chimeric antigen receptor as described in any one of claim 1-8,
It is characterized in that, its nucleotide sequence is as shown in SEQ ID NO.6.
10. as described in any one of claim 1-8, EpCAM specific chimeric antigen receptor is treated in preparation
Application in EpCAM related neoplasms medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610483048.1A CN105949323A (en) | 2016-06-24 | 2016-06-24 | EpCAM-specific chimeric antigen receptor and encoding gene and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610483048.1A CN105949323A (en) | 2016-06-24 | 2016-06-24 | EpCAM-specific chimeric antigen receptor and encoding gene and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105949323A true CN105949323A (en) | 2016-09-21 |
Family
ID=56905389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610483048.1A Pending CN105949323A (en) | 2016-06-24 | 2016-06-24 | EpCAM-specific chimeric antigen receptor and encoding gene and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105949323A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107602703A (en) * | 2016-08-12 | 2018-01-19 | 四川大学 | Target people EpCAM genetically engineered lymphocyte and its production and use |
| CN108795877A (en) * | 2018-07-05 | 2018-11-13 | 浙江科途医学科技有限公司 | A kind of Chimeric antigen receptor fibroblast and its method for building up and application |
| CN110194803A (en) * | 2019-06-26 | 2019-09-03 | 上海科棋药业科技有限公司 | A kind of Chimeric antigen receptor and its application targeting EpCAM |
| US20210145881A1 (en) * | 2018-04-09 | 2021-05-20 | Mayo Foundation For Medical Education And Research | Methods and materials for treating graft-versus-host disease |
| CN113527509A (en) * | 2020-04-17 | 2021-10-22 | 深圳华大生命科学研究院 | Application of compound containing recombinant protein and protective protein in treating lung squamous carcinoma |
| WO2023196953A3 (en) * | 2022-04-08 | 2023-11-09 | The Wistar Institute Of Anatomy And Biology | Combinations of bispecific t cell engagers and methods of use thereof |
| WO2023196954A3 (en) * | 2022-04-08 | 2023-11-30 | The Wistar Institute Of Anatomy And Biology | Bispecific binding molecules that target fshr and cd3 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1812999A (en) * | 2003-05-31 | 2006-08-02 | 麦克罗梅特股份公司 | Pharmaceutical composition comprising a bispecific antibody specific for EpCAM |
| CN103145849A (en) * | 2013-02-18 | 2013-06-12 | 冯振卿 | Chimeric antigen receptor and its use |
| CN103483452A (en) * | 2012-06-12 | 2014-01-01 | 上海吴孟超医学科技基金会 | Dual-signal independent chimeric antigen receptors (dsCAR) and uses thereof |
-
2016
- 2016-06-24 CN CN201610483048.1A patent/CN105949323A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1812999A (en) * | 2003-05-31 | 2006-08-02 | 麦克罗梅特股份公司 | Pharmaceutical composition comprising a bispecific antibody specific for EpCAM |
| CN103483452A (en) * | 2012-06-12 | 2014-01-01 | 上海吴孟超医学科技基金会 | Dual-signal independent chimeric antigen receptors (dsCAR) and uses thereof |
| CN103145849A (en) * | 2013-02-18 | 2013-06-12 | 冯振卿 | Chimeric antigen receptor and its use |
Non-Patent Citations (3)
| Title |
|---|
| NAOTO SHIRASU ET AL.: "Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM", 《JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY》 * |
| 张葵: "抗人EpCAM单链抗体的制备及其应用研究", 《中国博士学位论文全文数据库医药卫生科技辑》 * |
| 邓振领: "1靶向肿瘤干细胞抗原EpCAM的CAR-T细胞治疗前列腺癌的研究2射频消融抑制小鼠乳腺癌肺转移的实验硏究", 《中国博士学位论文全文数据库医药卫生科技辑》 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107602703A (en) * | 2016-08-12 | 2018-01-19 | 四川大学 | Target people EpCAM genetically engineered lymphocyte and its production and use |
| CN107602703B (en) * | 2016-08-12 | 2021-03-23 | 四川大学 | Human EpCAM targeted genetically engineered lymphocyte and preparation method and application thereof |
| US20210145881A1 (en) * | 2018-04-09 | 2021-05-20 | Mayo Foundation For Medical Education And Research | Methods and materials for treating graft-versus-host disease |
| CN108795877A (en) * | 2018-07-05 | 2018-11-13 | 浙江科途医学科技有限公司 | A kind of Chimeric antigen receptor fibroblast and its method for building up and application |
| CN108795877B (en) * | 2018-07-05 | 2021-07-09 | 浙江科途医学科技有限公司 | Chimeric antigen receptor fibroblast and establishing method and application thereof |
| CN110194803A (en) * | 2019-06-26 | 2019-09-03 | 上海科棋药业科技有限公司 | A kind of Chimeric antigen receptor and its application targeting EpCAM |
| CN110194803B (en) * | 2019-06-26 | 2021-01-05 | 上海科棋药业科技有限公司 | EpCAM-targeted chimeric antigen receptor and application thereof |
| CN113527509A (en) * | 2020-04-17 | 2021-10-22 | 深圳华大生命科学研究院 | Application of compound containing recombinant protein and protective protein in treating lung squamous carcinoma |
| CN113527509B (en) * | 2020-04-17 | 2023-09-26 | 深圳华大生命科学研究院 | Use of complexes containing recombinant proteins and protective proteins for the treatment of squamous cell lung carcinoma |
| WO2023196953A3 (en) * | 2022-04-08 | 2023-11-09 | The Wistar Institute Of Anatomy And Biology | Combinations of bispecific t cell engagers and methods of use thereof |
| WO2023196954A3 (en) * | 2022-04-08 | 2023-11-30 | The Wistar Institute Of Anatomy And Biology | Bispecific binding molecules that target fshr and cd3 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105949323A (en) | EpCAM-specific chimeric antigen receptor and encoding gene and application thereof | |
| Speck et al. | Targeted BiTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors | |
| CN104087607B (en) | The nucleic acid of encoding chimeric antigen receptor protein and the T lymphocytes of expression Chimeric antigen receptor albumen | |
| CN105925536A (en) | T lymphocyte modified by Trop2 chimeric antigen receptor and application thereof | |
| CN108409840B (en) | anti-CD 123 single-chain antibody, chimeric antigen receptor combined with same and application | |
| WO2017128534A1 (en) | Method for preparing pd-1/ctla-4 bispecific antibody and use thereof | |
| CN106480097A (en) | Knocking out that people PD 1 is gene constructed using CRISPR/Cas9 technology can the method for targeting MSLN novel C AR T cell and its application | |
| CN105602992A (en) | CAR-T transgene vector based on replication defective recombinant lentivirus and construction method and application of CAR-T transgene vector | |
| CN106117366A (en) | A kind of CD19 specific chimeric antigen receptor and encoding gene, application | |
| CN108440674A (en) | A kind of Trop-2 specific chimerics antigen receptor cell is prepared and application thereof | |
| CN111606999B (en) | Replicative oncolytic adenovirus with functions of activating immune co-stimulatory signaling pathway and blocking immune checkpoint and application thereof | |
| CN106117367B (en) | HER-3 specific chimeric antigen receptor and application thereof | |
| CN105906722A (en) | Her2 specific chimeric antigen receptor and application thereof | |
| CN105384824A (en) | Chimeric antigen receptor and gene and recombinant expression vector thereof, engineered HER2 targeting NKT cell and application thereof | |
| CN116143943B (en) | Targeting BAFFR chimeric antigen receptor, CAR-T cell and application | |
| CN107286247A (en) | BMDC of Chimeric antigen receptor modification containing anti-mesothelin single-chain antibody and application thereof | |
| CN113788894A (en) | Monoclonal antibody of targeted human Claudin18.2 protein and application thereof | |
| CN107287163B (en) | Express the dendritic cells and application thereof of Chimeric antigen receptor | |
| CN109705225B (en) | Chimeric antigen receptor resisting human CAIX antigen and application thereof | |
| CN109021114A (en) | Combine the bispecific chimeric antigen receptor and expression vector of two kinds of single-chain antibodies | |
| CN107793483B (en) | Chimeric antigen receptor and its gene and recombinant expression carrier, CARMSLN-NKT cell and its preparation method and application | |
| WO2020248486A1 (en) | Method for preparing car-t that uses tcm as main effective ingredient and use thereof | |
| WO2021139755A1 (en) | Engineered t cell, and preparation and use thereof | |
| CN105950662B (en) | A kind of replication defective recombinant slow virus CAR-T transgene carrier targeting CD22 and its construction method and application | |
| CN108395480A (en) | Chimeric antigen receptor and its gene and recombinant expression carrier, CARHER2-NKT cells and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |